Reply to: Increased Propensity for Pneumonia with Fluticasone in COPD.

Author Information: GSK, King of Prussia, Pennsylvania, United States.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; helen@thebarnacles.co.uk.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; ruby.k.birk@gsk.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; noushin.s.brealey@gsk.com.; GSK, King of Prussia, Pennsylvania, United States ; nicholas.w.locantore@gsk.com.; UCL Respiratory, University College London, London, United Kingdom of Great Britain and Northern Ireland ; d.lomas@ucl.ac.uk.; KLB Health Research, Lübeck, Germany ; a.ludwig@klb-healthresearch.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; mohindra.rajat@gmail.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; margaret.x.tabberer@gsk.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; chang-qing.2.zhu@gsk.com.; GSK, King of Prussia, Pennsylvania, United States ; steven.j.pascoe@gsk.com.